John B. Moriarty - 07 Jan 2026 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
Chief Legal Officer
Signature
/s/ Michael F. MacLean, Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
07 Jan 2026
Net transactions value
-$171,474
Form type
4
Filing time
09 Jan 2026, 17:12:57 UTC
Previous filing
19 Dec 2025
Next filing
27 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moriarty John B Chief Legal Officer C/O AVIDITY BIOSCIENCES, INC., 3020 CALLAN ROAD, SAN DIEGO /s/ Michael F. MacLean, Attorney-in-Fact 09 Jan 2026 0001564621

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Sale $171,474 -2,374 -3.1% $72.23 74,557 07 Jan 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.